Gene expression analysis during progression of malignant meningioma compared to benign meningioma.

Autor:	Maier AD; Departments of1Neurosurgery and.; 2Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Meddis A; 3Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark., Mirian C; Departments of1Neurosurgery and., Haslund-Vinding J; Departments of1Neurosurgery and., Bartek J; Departments of1Neurosurgery and.; 4Department of Neurosurgery, Karolinska University Hospital, Solna, Stockholm, Sweden.; 5Department of Clinical Neuroscience, Karolinska Institutet, Solna, Stockholm, Sweden., Krog SM; 6Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark., Nguyen TUP; 2Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Areškevičiūtė A; 7Department of Pathology, Danish Reference Center for Prion Diseases, Copenhagen University Hospital, Copenhagen, Denmark., Melchior LC; 2Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Heegaard S; 2Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; 8Department of Ophthalmology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Kristensen BW; 9Department of Clinical Medicine and Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark.; 10Department of Pathology, The Bartholin Institute, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Munch TN; Departments of1Neurosurgery and.; 11Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.; 17Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Fugleholm K; Departments of1Neurosurgery and., Ziebell M; Departments of1Neurosurgery and., Raleigh DR; Departments of12Neurological Surgery and.; 13Radiation Oncology, University of California, San Francisco, California., Poulsen FR; 14Department of Neurosurgery, Odense University Hospital, Odense, Denmark.; 15Clinical Institute and BRIDGE, University of Southern Denmark, Odense, Denmark; and., Gerds TA; 3Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark., Litman T; Departments of16Immunology and Microbiology and., Scheie D; 2Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Mathiesen T; Departments of1Neurosurgery and.; 17Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	Journal of neurosurgery [J Neurosurg] 2022 Sep 16; Vol. 138 (5), pp. 1302-1312. Date of Electronic Publication: 2022 Sep 16 (Print Publication: 2023).
DOI:	10.3171/2022.7.JNS22585
Abstrakt:	Objective: Meningioma is the most common primary intracranial neoplasm. Only 1%-3% of meningiomas are malignant according to the 2016 WHO criteria (WHO grade III). High-grade meningiomas present specific gene expression signatures indicating aggressive growth or recurrence. However, changes in gene expression and in neuroinflammatory gene expression signatures in WHO grade III meningiomas and during progression from WHO grade I or II to grade III are unknown. Methods: The authors used a NanoString targeted gene expression panel with focus on 787 genes relevant in meningioma pathology and neuroinflammatory pathways to investigate patients with grade III meningiomas treated at Rigshospitalet from 2000 to 2020 (n = 51). A temporal dimension was added to the investigation by including samples from patients' earlier grade I and II meningiomas and grade III recurrences (n = 139 meningiomas). The authors investigated changes in neuroinflammatory gene expression signatures in 1) grade I meningiomas that later transformed into grade III meningiomas, and 2) grade III meningiomas compared with nonrecurrent grade I meningiomas. Results: The authors' data indicate that FOXM1, TOP2A, BIRC5, and MYBL2 were enriched and the HOTAIR regulatory pathway was enriched in grade III meningiomas compared with nonrecurrent grade I meningiomas. They discovered a separation of malignant and benign meningiomas based only on genes involved in microglia regulation with enrichment of P2RY12 in grade I compared with grade III meningiomas. Interestingly, FOXM1 was upregulated in premalignant grade I meningioma years before the grade III transformation. Conclusions: The authors found gene expression changes in low-grade meningiomas that predated histological transformation to grade III meningiomas. Neuroinflammation genes distinguished grade III from grade I meningiomas.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu